Predicting skin toxicity according to EGFR polymorphisms in patients with colorectal cancer receiving antibody against EGFR.
OBJECTIVE
Monoclonal antibodies against epidermal growth factor receptor (EGFR) can extend progression-free survival (PFS) and overall survival (OS) in patients with unresectable colorectal cancer; however, skin toxicity often interferes with therapy continuation.


METHODS
We analyzed the polymorphisms in EGFR and IgG fragment C receptor (FCGR) genes and determined their associations with clinical outcomes including PFS, OS, and skin toxicity. Five polymorphisms in EGFR and FCGR genes in 32 patients with unresectable colorectal cancer who were treated with antibodies against EGFR were examined.


RESULTS
Patients carrying the C/C genotype of the EGFR D994D polymorphism displayed significantly less skin toxicity than those with other genotypes, although no significant differences in PFS and OS were noted and no significant interactions were detected for other gene polymorphisms.


CONCLUSIONS
These results suggest that the EGFR D994D polymorphism is a useful biomarker for predicting the severity of skin toxicity in patients receiving antibody against EGFR.
1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan. hideoszk@md.tsukuba.ac.jp.
Rie
R
Saito
Hideo
H
Suzuki
Takeshi
T
Yamada
Shinji
S
Endo
Toshikazu
T
Moriwaki
Takunori
T
Ueno
Mitsuaki
M
Hirose
Sachiko
S
Hirai
Kenji
K
Yamato
Yuji
Y
Mizokami
Ichinosuke
I
Hyodo
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D014408:Biomarkers, Tumor / Q000235:genetics*; D015179:Colorectal Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000150:complications / Q000188:drug therapy / Q000235:genetics; D009367:Neoplasm Staging; D011110:Polymorphism, Genetic / Q000235:genetics*; D011379:Prognosis; D017452:Receptors, IgG / Q000235:genetics; D012189:Retrospective Studies; D012871:Skin Diseases / Q000139:chemically induced / Q000235:genetics* / Q000401:mortality; D015996:Survival Rate
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; C445323:FCGR2A protein, human; C496124:FCGR3A protein, human; D017452:Receptors, IgG; C512478:EGFR protein, human; D066246:ErbB Receptors
EGFR antibody; EGFR gene polymorphism; colorectal cancer; skin toxicity